These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Points to consider: the roles of surveillance and epidemiology in advancing drug safety. Edwards R; Faich G; Tilson H; Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):665-7. PubMed ID: 15719353 [No Abstract] [Full Text] [Related]
15. Enhanced funding of pharmacoepidemiology through patenting the disclosure of adverse event information. Classen JB Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):390-3. PubMed ID: 16411171 [TBL] [Abstract][Full Text] [Related]
16. More lawyers. More bureaucrats. Less information on drug safety. Walker AM Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):394-5. PubMed ID: 16739244 [No Abstract] [Full Text] [Related]
17. Propensity score methods in drug safety studies: practice, strengths and limitations. Wang J; Donnan PT Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497 [No Abstract] [Full Text] [Related]
18. Data safety and drug safety in Germany: a closing gap? Rathmann W Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):625-30. PubMed ID: 11980251 [TBL] [Abstract][Full Text] [Related]
19. [Frequent drug interactions in general practice]. Bjerrum L; Andersen M; Petersen G; Kragstrup J Ugeskr Laeger; 2004 Sep; 166(39):3401-4. PubMed ID: 15515394 [No Abstract] [Full Text] [Related]
20. Looking to the 21st century: have we learned from our mistakes, or are we doomed to compound them? Shapiro S Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):257-65. PubMed ID: 15255093 [No Abstract] [Full Text] [Related] [Next] [New Search]